Navigation Links
Study of Cell Therapeutics' Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
Date:6/17/2012

SEATTLE, June 18, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). 

Drs. John Pagel and Elihu Estey, from the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, are leading the study.

"This is the first study to examine the effects of tosedostat in combination with either cytarabine or decitabine as a first-line therapy.  The study will evaluate how well patients tolerate these combinations, and their effectiveness.  Given that there have been no major advances in treatment of elderly patients with AML, and the results of a previous study of tosedostat by itself in relapsed or refractory patients with AML or MDS showed promising anti-leukemic effects and acceptable tolerability, we are hopeful that this study will demonstrate that tosedostat increases the limited efficacy of these commonly used anti-leukemic agents," Dr. Estey said.

The study's primary objectives are to determine the four-month survival and complete response ("CR") rates of tosedostat in combination with either cytarabine or decitabine in untreated AML or high-risk MDS. The study's secondary objectives are to assess the safety and tolerability of tosedostat in combination with either cytarabine or decitabine, to determine the treatment-related mortality rate (defined as death within the first 30 days of beginning treatment), and to estimate the rates of disease-free survival, one-year survival, and overall survival.   

About the Study

Each arm of the study will enroll up to 20 patients, with the possibility of enrolling an additional five patients each (for a ma
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... denying motions for judgment notwithstanding the verdict, a new ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript’s trade secrets, and that it ... The court entered an order denying motions for judgment ...
(Date:2/26/2015)... 2015 The Pittcon 2015 Exposition, ... Ernest N. Morial Convention Center in New Orleans, ... February 19, 2015) displaying products and services used ... government labs. The Exposition will offer the latest ... to, analytical chemistry; drug discovery; nanotechnology; life sciences ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2
... BEIJING, Aug. 30, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: ... in China, announced today that Dr. Weidong Yin, President and ... Helen Yang, Investor Relations Manager, are scheduled to attend four ... Rodman & Renshaw Annual Global Investment Conference, New ...
... ProteinSimple today introduced a revolutionary new system for protein analysis, ... complete reinvention of the Western Blot, and is truly a ... 30 years, researchers have access to a completely automated, walk-away ... was invented in 1979 and to this day remains the ...
... Technologies Corporation (NASDAQ: LIFE ) today announced ... Sciences Conference on Tuesday, September 20 at 8:00am ET. ... will present on behalf of the company. The company ... three weeks following the conference on the Life Technologies, ...
Cached Biology Technology:Sinovac to Participate in Four Investor Conferences in September 2011 2ProteinSimple Reinvents the Western Blot 2Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2
(Date:1/22/2015)... ROBERTS, Washington , January 20, 2015 ... and tech stocks, releases video from the CES 2015 (Consumer ... consultant Apollo Robbins . Apollo shows how ... biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its launch in ... of people to eliminate the pain of trying to remember ... their own biometrics fused to their smartphones. To assist people ... Labs , the company that created 1U and focuses on ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... research team has identified a lung protein that appears ... have crafted an antibody to block its activity, Indiana ... suggests that the protein, a cytokine named EMAPII, could ... Irina Petrache, M.D., associate professor of medicine at the ...
... , What does it take to regenerate a limb? Biologists ... and salamanders involved stem cells that can generate any tissue ... types are needed to regrow the complete organ, at least ... in St. Louis have shown that cells capable of regenerating ...
... (NPL) has worked with wireless sensor network developers ... degradation across critical structures in the UK that ... London-based Senceive,s main application area is long-term infrastructure ... are used to assess the condition of railway ...
Cached Biology News:Protein could offer target to reduce lung damage from smoking-caused emphysema 2Zebrafish regrow fins using multiple cell types, not identical stem cells 2NPL helps Senceive to offer improved monitoring of structural assets across the UK 2
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
Biology Products: